LY2603618

DRUG6 trials

Sponsors

Eli Lilly and Company

Conditions

Advanced CancerCancerNon Small Cell Lung CancerPancreatic NeoplasmsSolid Tumors

Phase 1

A Study for Participants With Pancreatic Cancer

CompletedNCT00839332

Eli Lilly and CompanyPancreatic Neoplasms

Start: 2009-02-28End: 2013-12-31Updated: 2018-04-17

A Study in Non Small Cell Lung Cancer

CompletedNCT01139775

Eli Lilly and CompanyNon Small Cell Lung Cancer

Start: 2011-02-28End: 2014-08-31Updated: 2018-05-18

C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors

CompletedNCT01296568

Eli Lilly and CompanyAdvanced Cancer

Start: 2011-02-28End: 2012-02-29Updated: 2019-01-07

A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors

CompletedNCT01341457

Eli Lilly and CompanySolid Tumors

Start: 2011-05-31End: 2016-07-31Updated: 2019-03-01

A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine

CompletedNCT01358968

Eli Lilly and CompanyCancer

Start: 2011-06-30End: 2012-12-31Updated: 2018-10-25

Phase 2

A Study of Advanced or Metastatic Non-small Cell Lung Cancer

CompletedNCT00988858

Eli Lilly and CompanyNon Small Cell Lung Cancer

Start: 2009-11-30End: 2014-11-30Updated: 2019-09-17

Related Papers

A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.

2017-03-0644 citations

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

BMC Cancer2017-02-1572 citations